{"disease":{"id":"pathologic-myopia","name":"Pathologic Myopia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"verteporfin","indication_name":"Pathologic Myopia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Visudyne","generic_name":"VERTEPORFIN","company_name":"Bausch Lomb Ireland","drug_phase":"marketed","molecular_target":"","drug_class":"Photoenhancer [EPC]","quality_score":10,"revenue":null,"mechanism":"Visudyne selectively binds to neovascular tissue, which is then activated by light to induce a phototoxic reaction."},{"drug_id":"visudyne","indication_name":"Pathologic Myopia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Visudyne","company_name":"Bayer","drug_phase":"discontinued","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03128463","title":"Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Xun Xu","has_results":false},{"nct_id":"NCT07249307","title":"High-throughput Large-model-based AI-assisted Diagnosis Using OCT","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT04723160","title":"Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph","phase":"","overall_status":"COMPLETED","enrollment_count":748,"lead_sponsor_name":"Visionary Intelligence Ltd.","has_results":false},{"nct_id":"NCT01922102","title":"Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":457,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06176352","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":280,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT02034006","title":"A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT07312214","title":"LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia","phase":"NA","overall_status":"RECRUITING","enrollment_count":158,"lead_sponsor_name":"Shanghai Eye Disease Prevention and Treatment Center","has_results":false},{"nct_id":"NCT03070717","title":"High Myopia: Extended and Longterm Observation of Pathologic Myopia Patients With the Risk for Developing a Myopic Choroidal Neovascularization (CNV)","phase":"","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06322433","title":"Follow up of High Myopic Eyes","phase":"","overall_status":"RECRUITING","enrollment_count":138,"lead_sponsor_name":"Istituto Auxologico Italiano","has_results":false},{"nct_id":"NCT03963596","title":"Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Myopia","phase":"NA","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"The Filatov Institute of Eye Diseases and Tissue Therapy","has_results":false},{"nct_id":"NCT04976244","title":"Brolucizumab for CNV Associated With Pathologic Myopia","phase":"NA","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"The Filatov Institute of Eye Diseases and Tissue Therapy","has_results":false},{"nct_id":"NCT07291960","title":"Retinal Clinical Assessment With AI-derived Quantitative Information","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":21,"lead_sponsor_name":"Beijing Tongren Hospital","has_results":false}],"total":12},"guidelines":[],"source":"Drug Landscape verified database"}